Ambrx Biopharma, Inc. (AMAM)

NYSE: AMAM · IEX Real-Time Price · USD
5.06 -0.28 (-5.24%)
Jan 21, 2022 4:00 PM EST - Market closed
Market Cap176.87M
Revenue (ttm)13.67M
Net Income (ttm)-16.54M
Shares Out34.96M
EPS (ttm)-4.97
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume19,613
Open5.30
Previous Close5.34
Day's Range4.88 - 5.68
52-Week Range4.90 - 22.87
Betan/a
AnalystsStrong Buy
Price Target28.00 (+453.4%)
Earnings Daten/a

About AMAM

Ambrx Biopharma Inc., a clinical-stage biologics company, focuses on discovering and developing engineered precision biologics using its proprietary expanded genetic code technology platform. Its lead product candidate is ARX788, an anti-HER2 antibody-drug conjugate (ADC), which is investigated in various clinical trials for the treatment of breast cancer, gastric/gastroesophageal junction cancer, and other solid tumors, including ongoing Phase 2/3 clinical trials for the treatment of HER2-positive metastatic breast cancer and gastric cancer. T...

IndustryBiotechnology
IPO DateJun 18, 2021
Employees70
Stock ExchangeNYSE
Ticker SymbolAMAM
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for AMAM stock is "Strong Buy." The 12-month stock price forecast is 28.00, which is an increase of 453.36% from the latest price.

Price Target
$28.00
(453.36% upside)
Analyst Consensus: Strong Buy

News

Ambrx Biopharma (AMAM) Sees Hammer Chart Pattern: Time to Buy?

Ambrx Biopharma (AMAM) has been struggling lately, but the selling pressure may be coming to an end soon.

3 weeks ago - Zacks Investment Research

Ambrx Biopharma Shares Jump After Safety, Efficacy Data From Breast Cancer Trial

Ambrx Biopharma Inc's (NYSE: AMAM) partner in China, NovoCodex Pharmaceuticals Ltd, presented favorable safety and efficacy data from its ongoing ACE-Breast-01 Phase 1 study of ARX788 at the San Antonio...

1 month ago - Benzinga

Ambrx Biopharma Inc. Presents Positive Data from Ongoing ACE-Breast-01 Phase 1 Clinical Study of ARX788 at San Antoni...

SAN DIEGO--(BUSINESS WIRE)--Ambrx Biopharma Inc. Presents Positive Data from Ongoing ACE-Breast-01 Phase 1 Clinical Study of ARX788 at San Antonio Breast Cancer Symposium

1 month ago - Business Wire

Ambrx Biopharma Inc. Announces Acceptance of Two Poster Presentations at the 2021 San Antonio Breast Cancer Symposium

SAN DIEGO--(BUSINESS WIRE)--Ambrx Biopharma Inc. Announces Acceptance of Two Poster Presentations at the 2021 San Antonio Breast Cancer Symposium

2 months ago - Business Wire

Ambrx Biopharma Inc. Announces First Patient Dosed in its Global Phase 2 ACE-Breast-03 Clinical Study of ARX788 for t...

SAN DIEGO--(BUSINESS WIRE)--Ambrx Announces First Patient Dosed in Global Phase 2 ACE-Breast-03 Clinical Study of ARX788 for Treatment of HER2-Positive Metastatic Breast Cancer

2 months ago - Business Wire

Ambrx Biopharma Inc. to Present at the 30th Annual Virtual Credit Suisse Healthcare Conference

SAN DIEGO--(BUSINESS WIRE)--Ambrx Biopharma Inc. to Present at the 30th Annual Virtual Credit Suisse Healthcare Conference

2 months ago - Business Wire

Ambrx Biopharma Inc. Reports 1H 2021 Financial Results and Provides Corporate Update

SAN DIEGO--(BUSINESS WIRE)--Ambrx Biopharma Inc. Reports 1H 2021 Financial Results and Provides Corporate Update

2 months ago - Business Wire

Ambrx Announces Positive Data on ARX788 for the Treatment of HER2+ Gastric Cancer Presented at CSCO

SAN DIEGO--(BUSINESS WIRE)--Ambrx Announces Positive Data on ARX788 for the treatment of HER2+ Gastric Cancer Presented at CSCO

3 months ago - Business Wire

Ambrx to Participate in Panel Discussion at the H.C. Wainwright 23rd Annual Global Investment Conference

SAN DIEGO--(BUSINESS WIRE)--Ambrx to Participate in Panel Discussion at the H.C. Wainwright 23rd Annual Global Investment Conference

4 months ago - Business Wire

Ambrx Announces First Patient Dosed in a Phase 1 Trial for ARX517, an ADC in Development to Treat PSMA Expressing Tumors

SAN DIEGO--(BUSINESS WIRE)--Ambrx Announces First Patient Dosed in a Phase 1 Trial for ARX517, an ADC in Development to Treat PSMA Expressing Tumors

5 months ago - Business Wire

Ambrx Appoints Sonja Nelson as Chief Financial Officer

SAN DIEGO--(BUSINESS WIRE)--Ambrx Appoints Sonja Nelson as Chief Financial Officer

6 months ago - Business Wire

Ambrx Announces Pricing of Initial Public Offering

SAN DIEGO--(BUSINESS WIRE)--Ambrx Announces Pricing of Initial Public Offering

7 months ago - Business Wire